Comparsion of effecacy and safety of glimepiride and sitagliptin

Comparison of the efficacy and safety of glimepiride and sitagliptin in type 2 diabetes: a randomized crossover trial.

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000033709

Enrollment

Unknown

Registered

2020-06-10

Start date

2020-07-01

Completion date

Unknown

Last updated

2020-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Interventions

Glim:glimepiride

Sita:sitagliptin

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients aged 18-75 years; 2. Patients newly diagnosed with type 2 diabetes; 3. HbA1c > = 7.5%, < 11.0% patients.

Exclusion criteria

Exclusion criteria: 1. Patients with transaminase > 3 times of upper limit and creatinine > normal upper limit; 2. Tumor, pregnant women, lactation.

Design outcomes

Primary

Measure	Time frame
HbA1c;	—

Secondary

Measure	Time frame
hypoglycemia;	—

Countries

China

Contacts

Public ContactWangen Li

The Second Affiliated Hospital of Guangzhou Medical University

liwg660@126.com+86 13500031715

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026